Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: A 2-year follow-up study

Clinical Endocrinology

Volumn 73, Issue 3, 2010, Pages 305-312

  Berberoglu, Zehra ^a   Yazici, Ayse C ^b   Demirag, Nilgun G ^c  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c Department of Endocrinology and Metabolism   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; DEOXYPYRIDINOLINE; OSTEOCALCIN; ROSIGLITAZONE;

ADULT; ARTICLE; BONE METABOLISM; BONE MINERAL; BONE REMODELING; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFECT; FEMALE; FEMUR NECK; FOLLOW UP; GREATER TROCHANTER; HUMAN; LUMBAR SPINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955741428     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03784.x     Document Type: Article

References (26)

1. Henry, R.R. (1997) Thiazolidinediones. Endocrinology and metabolism clinics of North America, 26, 553 573.
2. Grey, A., Bolland, M., Gamble, G. et al. (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. The Journal of clinical endocrinology and metabolism, 92, 1305 1310.
3. Berberoglu, Z., Gursoy, A., Bayraktar, N. et al. (2007) Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. The Journal of clinical endocrinology and metabolism, 92, 3523 3530.
4. Rzonca, S.O., Suva, L.J., Gaddy, D. et al. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology, 145, 401 406.
5. Akune, T., Ohba, S., Kamekura, S. et al. (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. The Journal of clinical investigation, 113, 846 855.
6. Ali, A.A., Weinstein, R.S., Stewart, S.A. et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology, 146, 1226 1235.
7. Okazaki, R., Miura, M., Toriumi, M. et al. (1999) Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocrine journal, 46, 795 801.
8. Watanabe, S., Takeuchi, Y., Fukumoto, S. et al. (2003) Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. Journal of bone and mineral metabolism, 21, 166 171.
9. Schwartz, A.V., Sellmeyer, D.E., Vittinghoff, E. et al. (2006) Thiazolidinedione (TZD) use and bone loss in older diabetic adults. The Journal of clinical endocrinology and metabolism, 91, 3349 3354.
10. Kahn, S.E., Haffner, S.M., Heise, M.A. et al., ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England journal of medicine, 355, 2427 2443 [Erratum in: The New England journal of medicine 2007; 356(13), 1387-1388].
11. Glintborg, D., Andersen, M., Hagen, C. et al. (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. The Journal of clinical endocrinology and metabolism, 93, 1696 1701.
12. American Diabetes Association (2001) Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care, 24 (Suppl. 1 S44 S47.
13. Matthews, D.R., Hosker, J.P., Rudenski, A.S. et al. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412 419.
14. Rubin, G.L., Zhao, Y., Kalus, A.M. et al. (2000) Peroxisome proliferator-activated receptor gamma γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer research, 60, 1604 1608.
15. Arlt, W., Auchus, R.J. Miller, W.L. (2001) Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. The Journal of biological chemistry, 276, 16767 16771.
16. Van Staa, T.P., Leufkens, H.G.M. Cooper, C. (2002) The Epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis international, 13, 777 787.
17. Kahn, S.E., Zinman, B., Lachin, J.M. et al. (2008) Rosiglitazone- associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, 31, 845 851.
18. Heiss, C.J., Sanborn, C.F., Nichols, D.L. et al. (1995) Associations of body fat distribution,circulating sex hormones,and bone density in postmenopausal women. The Journal of clinical endocrinology and metabolism, 80, 1591 1596.
19. Ensrud, K.E., Lipschutz, R.C., Cauley, J.A. et al. (1997) Body size and hip fracture risk in older women: a prospective study. Study of Osteoporotic Fractures Research Group. The American journal of medicine, 103, 274 280.
20. Schott, A.M., Cormier, C., Hans, D. et al. (1998) How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporosis international, 8, 247 254.
21. Nguyen, N.D., Pongchaiyakul, C., Center, J.R. et al. (2005) Abdominal fat and hip fracture risk in the elderly: the Dubbo Osteoporosis Epidemiology Study. BMC musculoskeletal disorders, 2005 Feb 23; 6 : 11.
22. Sornay-Rendu, E., Munoz, F., Duboeuf, F. et al. (2005) Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study. Journal of bone and mineral research, 20, 1929 1935.
23. Loke, Y.K., Singh, S. Furberg, C.D. (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. The Canadian Medical Association Journal, 180, 32 39.
24. Home, P.D., Pocock, S.J., Beck-Nielsen, H. et al., for the RECORD Study Team (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 373, 2125 2135.
25. Sanders, K.M., Seman, E., Ugoni, A.M. et al. (1999) Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporosis International, 10, 240 247.
26. Chappard, D., Moquereau, M., Mercier, P. et al. (2004) Ex vivo bone mineral density of the wrist: influence of medullar fat. Bone, 34, 1023 1028.